Semaglutide Spending Surges: What It Means for Canadian Drug Plans
GreenShield reports a 47.7% jump in semaglutide costs, driven by rising chronic disease rates and growing demand for GLP-1 medications. The trend is reshaping how Canadian employers and insurers approach drug plan coverage and sustainability.
What happened
GreenShield has flagged a 47.7% increase in semaglutide costs on its drug plan books, pointing to rising rates of chronic disease as a key driver of overall prescription spending. The data highlights how quickly GLP-1 medications, originally developed for type 2 diabetes and now widely used for weight management, are reshaping employer-sponsored health benefits in Canada.
What it means for consumers
Canadians covered by private drug plans that include semaglutide may soon encounter tighter access controls, including stricter prior authorization, step therapy requirements, or revised eligibility criteria. For those without robust supplemental coverage, the out-of-pocket cost of these medications remains substantial, making employer or private plan design a critical factor in affordability.
What it means for premiums
No direct premium change has been announced.
Coverage considerations
Plan sponsors are likely to revisit formularies to differentiate between medically necessary diabetes use and elective weight-loss prescriptions, with the latter increasingly subject to limits, annual caps, or exclusion. Employees should review their plan summaries closely, as coverage terms for GLP-1 drugs can shift quickly in response to cost trends.